Research Feed
PROSERA Failed. Drug Works. Doesn't Matter.
PROSERA Phase 3 missed its primary endpoint. Seralutinib improved 6MWD by +28.2m from baseline versus +13.5m for placebo. Hodges-Lehmann treatment effect: +13.3 meters. P-value: 0.0320. Prespecified threshold: 0.025. Trial failed. The miss triggers hierarchical testing failure — none of the four key